By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sorrento Therapeutics, Inc. 

6042 Cornerstone Court W,

San Diego  California  92121  U.S.A.
Phone: n/a Fax: n/a



Company News
Sorrento Announces Positive Data From Phase 3 Studies Of Biosimilar Antibodies, STI-001 And STI-002 1/11/2016 6:35:45 AM
Sorrento And Karolinska Institutet Establish Exclusive Partnership For Research And Development Of Natural Killer Cell-Based Therapies 1/11/2016 6:20:09 AM
Sorrento Release: Upcoming Corporate Presentations In San Francisco 1/8/2016 8:40:37 AM
Sorrento Expands Its Executive Management Team With Appointment Of Dr. Jeffrey Su As Chief Operating Officer To Lead Its In-House Bioprocess And Manufacturing Operations 10/19/2015 9:30:42 AM
Sorrento To Present At Aegis Capital Corporation 2015 Growth Conference 10/9/2015 7:30:28 AM
Sorrento Inks $170 Million Exclusive Deal With City of Hope 9/28/2015 8:34:10 AM
Sorrento To Present At Upcoming Conferences 9/9/2015 8:19:47 AM
Sorrento And Its Wholly-Owned Subsidiary, TNK Therapeutics, To Exclusively License CytoLumina's NanoVelcro Circulating Tumor Cell Profiling Assay 8/11/2015 7:03:06 AM
Sorrento Unit Buys CAR-T Programs, Technology for Undisclosed Sum 8/10/2015 6:12:03 AM
Sorrento In-Licenses Four Late-Stage Clinical Biobetter And Biosimilar Antibodies 8/3/2015 6:38:10 AM